Does UnitedHealthcare Cover ADHD Treatment in Delaware? A 2026 Guide

Last updated: July 21, 2026

If you have UnitedHealthcare (UHC) insurance in Delaware and are seeking ADHD treatment, understanding your coverage may help you access care more efficiently. UHC commercial plans in Delaware typically cover ADHD medication and behavioral health services under the same terms as medical benefits, in compliance with Delaware’s mental health parity law. This guide covers what Delaware residents may expect from UnitedHealthcare coverage for ADHD, including formulary details, prior authorization requirements, and electronic prescribing rules.

Key facts for UHC members in Delaware:
• Insurer: UnitedHealthcare (UHC) | PBM: OptumRx
• State parity law: Del. Code Ann. tit. 18, § 3343. Requires mental health and substance use disorder benefits on par with medical/surgical benefits
• Federal parity: Mental Health Parity and Addiction Equity Act (MHPAEA, 29 U.S.C. § 1185a)
• Delaware EPCS: Schedule II stimulants require electronic prescribing under Delaware Board of Medical Licensure regulations (DE Admin Code, Title 24, § 1700); non-stimulants (non-scheduled) are exempt
• Prior authorization: Brand-name stimulants and non-stimulant alternatives typically require PA and step therapy under OptumRx
• Contacts: UHC Member Services 1-866-774-2884 | OptumRx 1-800-788-4863 | DE Insurance Commissioner 1-302-674-7300

Check if your UHC plan may cover ADHD treatment in Delaware: See if you may qualify at Klarity Health

Delaware Mental Health Parity and ADHD

Delaware’s parity law (Del. Code Ann. tit. 18, § 3343) requires health insurers to provide mental health and substance use disorder benefits at parity with medical and surgical benefits. ADHD is recognized as a mental health condition under MHPAEA and Delaware law, meaning UHC commercial plans may not impose more restrictive treatment limitations for ADHD care than for comparable medical conditions. In practice, this means deductibles, copays, prior authorization criteria, and visit limits for ADHD services should be comparable to those applied to medical/surgical benefits under your specific plan.

Coverage details vary significantly by plan type (HMO, PPO, EPO), employer, and plan year. Always verify your specific benefits with UHC before scheduling an appointment.

UnitedHealthcare ADHD Medication Formulary (OptumRx)

UHC uses OptumRx to manage pharmacy benefits for most commercial plans. Under OptumRx, ADHD medications are generally organized into tiers based on cost and clinical preference. The following table reflects typical commercial formulary placements, which may vary by specific plan:

Formulary tiers and PA requirements vary by plan. Verify your specific plan’s drug list at uhc.com or call OptumRx at 1-800-788-4863.

Prior Authorization and Step Therapy for ADHD Medications

Under many UHC/OptumRx commercial plans, prior authorization (PA) is typically required for brand-name stimulants and some non-stimulant alternatives. Step therapy requirements may mean that a member needs to try and document a trial of a generic stimulant before brand coverage is approved. Common PA criteria for brand stimulants may include:

• Documentation of a prior trial of at least one generic stimulant at an adequate dose and duration
• A diagnosis of ADHD confirmed by a licensed provider
• Clinical justification for the brand formulation (e.g., patient cannot use the generic equivalent)

For non-stimulants such as Strattera or Qelbree, PA criteria may require documentation that stimulants were contraindicated, not tolerated, or clinically inappropriate. If your PA request is denied, you have the right to file an internal appeal with UHC and, if necessary, an external review through the Delaware Department of Insurance.

Delaware EPCS Requirements for ADHD Medications

Delaware requires electronic prescribing for controlled substances under Delaware Board of Medical Licensure regulations. For ADHD medications, this means:

Telehealth providers prescribing stimulants in Delaware must use a certified EPCS platform. Non-stimulant ADHD medications are not controlled substances and are not subject to EPCS requirements, making them more straightforward to prescribe via telehealth.

How to Appeal a Denied ADHD Claim in Delaware

If UHC denies coverage for ADHD medication or a related service, you have several options:

1. Internal appeal: File a written appeal with UHC within the timeframe specified in your denial letter (typically 180 days). UHC must review and respond within required timelines.
2. External review: If your internal appeal is upheld, you may request an independent external review through the Delaware Department of Insurance.
3. Delaware DOI complaint: Contact the Delaware Department of Insurance at 1-302-674-7300 to file a complaint about a coverage denial you believe violates Delaware parity law (Del. Code Ann. tit. 18, § 3343) or MHPAEA.
4. DOL EBSA: For employer-sponsored plans governed by ERISA, contact the U.S. Department of Labor Employee Benefits Security Administration (EBSA) at 1-866-444-3272.

Get ADHD Treatment Through Klarity Health

Klarity Health connects Delaware residents with 2,000+ licensed providers who offer online ADHD evaluation and treatment. Klarity providers can assess your symptoms, confirm an ADHD diagnosis, and prescribe appropriate medications using a certified EPCS platform where required. Non-stimulant alternatives may be prescribed more easily for patients who prefer a telehealth-first approach.

Coverage for telehealth ADHD services may vary by UHC plan. We recommend verifying your benefits before your first visit.

Check if your UHC plan may cover ADHD treatment. See if you may qualify

Frequently Asked Questions

Does UnitedHealthcare cover ADHD diagnosis in Delaware?
UHC commercial plans often cover ADHD evaluations and diagnostic assessments as behavioral health services. Coverage varies by plan and provider network. Verify your specific benefits with UHC member services.

Does UHC cover Vyvanse in Delaware?
Vyvanse (lisdexamfetamine) is often covered under UHC/OptumRx formularies, but it typically requires prior authorization and may require a documented trial of a generic stimulant first. Check your plan’s current PDL for Vyvanse tier placement.

Can I get ADHD medication prescribed via telehealth in Delaware?
Yes. Delaware permits telehealth prescribing for ADHD medications, including Schedule II stimulants, when providers use a certified EPCS system. Non-stimulant ADHD medications may be prescribed without EPCS requirements.

What happens if UHC denies my ADHD medication PA request?
You may file an internal appeal with UHC and, if denied again, request external review through the Delaware DOI (1-302-674-7300). Employer plan members may also contact DOL EBSA (1-866-444-3272).

Does Delaware parity law require UHC to cover ADHD treatment?
Del. Code Ann. tit. 18, § 3343 requires that mental health benefits, including ADHD services, be covered at parity with medical/surgical benefits. This does not guarantee coverage of every specific drug or service, but it does limit UHC from imposing disproportionately restrictive limits on ADHD care.

What is OptumRx and does it manage my UHC pharmacy benefits?
OptumRx is UHC’s pharmacy benefit manager (PBM). Most UHC commercial plans in Delaware use OptumRx to process prescription drug claims and manage the formulary. Contact OptumRx at 1-800-788-4863 for formulary questions.

Key Contacts

• UnitedHealthcare Member Services: 1-866-774-2884
• OptumRx (pharmacy): 1-800-788-4863
• Delaware Department of Insurance: 1-302-674-7300
• DOL EBSA (ERISA plans): 1-866-444-3272

Disclaimer: Coverage details vary by plan, employer, and plan year. This page is for informational purposes only and does not constitute insurance advice. Always verify your specific benefits with UnitedHealthcare before booking an appointment. Coverage is not guaranteed.